Mayo Clinic approves clinical study of HeraMED’s HeraBEAT device
Health & Biotech
Health & Biotech
Link copied to
Special Report: World-renowned medical centre, Mayo Clinic, has approved HeraMED’s HeraBEAT device for a clinical study to begin later this month.
Mayo Clinic has approved a clinical study of HeraMED’s (ASX:HMD) HeraBEAT device, to begin in December 2020.
The study will be conducted at the Department of Obstetrics and Gynaecology at Mayo Clinic in Rochester, Minnesota and will recruit 50 low-risk expectant mothers.
Headquartered in Minnesota, USA, Mayo Clinic operates as a not-for-profit, academic medical organisation focused on integrating clinical practice, education and research and employs over 4,500 physicians and scientists. The Mayo Clinic is considered one of the world’s leading medical institutions and was ranked first in the US News & World Report 2019-2020 ‘Best Hospitals Honour Roll’ rankings.
The Mayo Clinic services approximately 2,500 pregnancies per year. Their pioneering OB Nest program demonstrated the medical benefits of virtual prenatal care.
HeraMED CEO and co-founder, David Groberman, said the agreement marked an important step in the company’s well-defined commercialisation strategy by aligning itself with leading healthcare providers and medical institutions.
“The approval to commence a clinical study with a world-leading healthcare provider, such as Mayo Clinic, is a significant milestone for HeraMED. Mayo Clinic represents a highly relevant collaborator for HeraMED because they are well renowned as leading researchers in advancing prenatal care models,” said Groberman.
“We are delighted to be commencing this study under Mayo Clinic’s OB Nest program, an innovative virtual maternity care program that combines traditional prenatal care office visits with connected care visits and in-home monitoring.
“Our strategy is to cooperate with top-tier healthcare providers to drive adoption and this clinical study represents an extension to our existing collaboration with Mayo Clinic and aligns perfectly with our strategic goals. This trial is expected to be a precursor to the broader HeraCARE pilot.”
The trial represents the second clinical study of HeraBEAT, following outstanding results in Western Australia at the Joondalup Health Campus.
Mayo Clinic will assess the functionality, usability, and user acceptability of HeraMED’s services, as well as evaluate the impact of the device on the perception of foetal wellbeing felt by the expectant mothers. Using a smartphone interface, the HeraBEAT device provides real-time instructions for users of both foetal heart rate (FHR) and maternal heart rate (MHR).
The solution forms part of the HeraCARE platform which allows the measurement to be shared on a smart dashboard in a secure and confidential manner, to ensure proper support for women using the device at home with medical supervision, analysis, and advice.
The second trial follows a partnership with US maternity telehealth service, Teleperinatal, which enters HeraMED into the lucrative employee benefits industry.
This article was developed in collaboration with HeraMED, a Stockhead advertiser at the time of publishing.
This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.